Hiporfin photodynamic therapy for early-stage cervical cancer: A case report
Yu Liu1, Ruifang Wu1, Changzhong Li1
1Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen, China; Institute of Obstetrics and Gynecology, Shenzhen Peking University-Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Shenzhen, China; Shenzhen Key Laboratory on Technology for Early Diagnosis of Major Gynecologic Diseases, Peking University Shenzhen Hospital, Shenzhen, China.
Abstract:
A 28-year-old female patient, diagnosed with stage IA1 cervical cancer, received PDT treatment with intravenous injection of Hiporfin, a HpD type photosensitizer. The patient's human papillomavirus (HPV) and cytology testing results were negative at the 3-month. At 6 months, the lesions on the cervical surface and within the cervical canal had completely resolved. There were no signs of recurrence or HPV infection during the 12-month follow-up period. There were no serious adverse events reported during or after the PDT treatment.
